Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021
March 09 2021 - 1:00AM
Geneva, Switzerland, March 9,
2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage
pharmaceutical company pioneering allosteric modulation-based drug
discovery and development, announced today that it will issue its
full-year 2020 financial results on Thursday March 11, 2021.
Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of
Discovery Biology will provide a business update and review its
pipeline during a teleconference and webcast for investors,
analysts and the media on Thursday, March 11, 2021 at 16:00 CET
(15:00 GMT / 10:00 EST / 07:00 PST).
Title:
Addex to announce full-year 2020 financial
resultsDate:
March 11,
2021Time:
16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST).
Joining the Conference
Call:1: In the 10 minutes prior to the call start time,
call the appropriate participant dial-in
number. Dial-In Numbers:
-
Switzerland
+41 44 580 65 22
-
UK
+44 20 30 09 24 70
-
U.S.A
+1 87 74 23 08 30
- Other Countries
2: Provide the Operator with the
Participation Pin Code:
92320595#
Link to live event online:1: In
the 10 minutes prior to the call start time, sign in online by
following this Webex link.2: Password: Welcome
About Addex Therapeutics:Addex
Therapeutics is a clinical-stage pharmaceutical company focused on
the development and commercialization of an emerging class of novel
orally available small molecule drugs known as allosteric
modulators for neurological disorders. Allosteric modulators offer
several potential advantages over conventional non-allosteric
molecules and may offer an improved therapeutic approach to
conventional "orthosteric" small molecule or biological drugs.
Addex's allosteric modulator drug discovery platform targets
receptors and other proteins that are recognized as essential for
therapeutic intervention. Addex's lead drug candidate, dipraglurant
(mGlu5 negative allosteric modulator or NAM), is poised to start a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also
investigating dipraglurant's therapeutic use in blepharospasm (a
type of dystonia), for which a clinical trial is expected to be
initiated in H1 2021. Addex's third clinical program, ADX71149
(mGlu2 positive allosteric modulator or PAM), developed in
collaboration with Janssen Pharmaceuticals, Inc, is scheduled to
enter a phase 2a proof of concept clinical study for the treatment
of epilepsy in Q2 2021. Addex’s GABAB PAM program has been licensed
to Indivior PLC who are focused on development for the treatment of
addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7
NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4
PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative
disorders. Addex is listed on the SIX Swiss Exchange and the NASDAQ
Capital Market and trades under the ticker symbol "ADXN".
Press Contacts:
Tim DyerChief Executive OfficerTelephone: +41 22 884 15
55 PR@addextherapeutics.com |
Mike SinclairPartner, Halsin Partners+44 (0)20 7318
2955msinclair@halsin.com |
James Carbonara
Hayden IR (646)-755-7412 james@haydenir.com |
Forward Looking Statements:This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including in respect of the anticipated initiation of
clinical trials. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release, are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, uncertainties related to market conditions. These and
other risks and uncertainties are described in greater detail in
the section entitled “Risk Factors” in Addex Therapeutics’ Annual
Report on Form 20-F for the year ended December 31, 2019, as filed
with the SEC on April 27, 2020, the prospectus related to the
global offering and other filings that Addex Therapeutics may make
with the SEC in the future. Any forward-looking statements
contained in this press release represent Addex Therapeutics’ views
only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. Addex
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Aug 2023 to Aug 2024